Substance use stigma makes it difficult to reframe the opioid crisis as a public health issue and has been a barrier to accessing life-saving treatments. Interventions using people that convey recovery stories are promising practices. Groups that may benefit from targeted stigma reduction interventions include opioid users (to combat shame and blame), at-risk youth, first responders, dispensary personal, media, and healthcare professionals. The evidence supporting antistigma interventions is thin, with little Canadian research. Research is needed to establish the effectiveness of substance-related stigma reduction strategies. Health leaders should examine their own responsibilities to lead the public health debate, reduce opioid-related stigma, and actively engage members of the community of those with lived experience to become partners in these activities.
Get full access to this article
View all access options for this article.
References
1.
WakemanSE. Using science to battle stigma in addressing the opioid epidemic: opioid agonist therapy saves lives. Am J Med. 2016;129(5):455–456.
2.
PearlmanJ. Combatting Massachusetts's opioid epidemic: reducing the social stigma of addiction through increased access to voluntary treatment services and expansion of mandatory clinician education programs. Am J Law Med. 2016;42(4):835–857.
3.
FischerTChinATKuoIKirstMVlahovD. Canadian illicit opiate users’ views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse. 2002;37(4):495–522.
4.
LinkBGPhelanJC. Conceptualizing stigma. Annual Review of Sociology. 2001;27(6):363–385.
5.
StuartH. Reducing the stigma of mental illness. Glob Ment Health. 2016;3:1–14.
6.
StuartHSartoriusNThornicroftG. Fighting mental illness related stigma—what we have learned. In: JavedAFountoulakisKN, eds. Advances in Psychiatry. Cham, Switzerland: Springer International; 2019:621–635.
7.
CorriganPWMorrisSBMichaelsPJRafaczJDRüschN. Challenging the public stigma of mental illness: a meta-analysis of outcome studies. Psychiatr Serv. 2012;63(10):963–973.
8.
StuartHChenSPChristieR. Opening minds in Canada: background and rationale. Can J Psychiatry. 2014;59(10 suppl 1):S8–S12.
9.
StuartHChenSPChristieR. Opening minds in Canada: targeting change. Can J Psychiatry. 2014;59(10 suppl 1):S13–S18.
10.
Arboleda-FlórezJStuartH. From sin to science: fighting the stigmatization of mental illnesses. Can J Psychiatry. 2012;57(8):457–463.
11.
CrispAHGelderMGRixSMeltzerHIRowlandsOJ. Stigmatisation of people with mental illnesses. Br J Psychiatry. 2000;177:4–7.
12.
CorriganPWKuwabaraSAO’ShaughnessyJ. The public stigma of mental illness and drug addiction. J Soc Work. 2009;9(2):139–147.
13.
MartinJKPescosolidoBATuchSA. Of fear and loathing: the role of ‘disturbing behavior,’ labels, and causal attributions in shaping public attitudes toward people with mental illness. J Health Soc Behav. 2000;41:208–223.
RoomR. Stigma, social inequality and alcohol and drug use. Drug Alcohol Rev. 2005;24(2):143–155.
17.
WilliamsonLThomBStimsonGVUhlA. Stigma as a public health tool: implications for health promotion and citizen involvement. Int J Drug Policy. 2014;25(3):333–335.
18.
PescosolidoBMonahanJLinkBGStueveAKikuzawaS. The public’s view of the competence, dangerousness, and need for legal coercion of persons with mental health problems. Am J Public Health. 1999;89(9):1339–1345.
19.
van BoekelLC. Public opinion on imposing restrictions to people with an alcohol or drug addiction: a cross-sectional survey. Soc Psychiatry Psychiatr Epidemiol. 2007;48:2007–2016.
20.
RobertsonRDVanlaarWGM. Canada’s Impaired Driving Framework: The Way Forward. Ottawa, Canada: Traffic Injury Research Foundation; 2012.
21.
AnsticeSStrikeCJBrandsB. Supervised methadone consumption: client issues and stigma. Subst Use Misuse. 2009;44(6):794–808.
22.
VallerandAPNowakL. Chronic opioid therapy for nonmalignant pain: the patient’s perspective. Part II--barriers to chronic opioid therapy. Pain Manag Nurs. 2010;11(2):126–131.
23.
OlsenYSharfsteinJM. Confronting the stigma of opioid use disorder--and its treatment. JAMA. 2014;311(14):1393–1394.
24.
VigilantLG. The stigma paradox in methadone maintenance: naive and postive consequences of a “treatment punishment” approach to opiate addiction. Humanity Soc. 2004;28(4):403–418.
25.
EarnshawVSmithLCopenhaverM. Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma. Int J Ment Health Addict. 2013;11(1):110–122.
26.
CooperSNielsenS. Stigma and social support in pharmaceutical opioid treatment populations: a scoping review. Int J Ment Health Addict. 2014;15(2):452–469.
27.
BrenerLvon HippelWvon HippelCResnickITreloarC. Perceptions of discriminatory treatment by staff as predictors of drug treatment completion: utility of a mixed methods approach. Drug Alcohol Rev. 2010;29(5):491–497.
28.
LloydC. The stigmatization of problem drug users: a narrative literature review. Drugs: Education, Prevention and Policy. 2013;20(2):85–95.
Kennedy-HendricksABarryCLGollustSEEnsmingerMEChisolmMSMcGintyEE. Social stigma toward persons with prescription opioid use disorder: associations with public support for punitive and public health-oriented policies. Psychiatr Serv. 2017;68(5):462–469.
Canadian Journalism Forum on Violence and Trauma. Minset Media Guide. Ottawa, Ontario, Canada: The Mental Health Commission of Canada; 2015.
38.
McGintyEEGoldmanHHPescosolidoBBarryCL. Portraying mental illness and drug addiction as treatable health conditions: effects of a randomized experiment on stigma and discrimination. Soc Sci Med. 2015;126:73–85.
Standing Committee on Health. Report and Recommendations on the Opioid Crisis in Canada. Ottawa, Ontario, Canada: The Standing Committee on Health; 2016.
